Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The long-term efficacy and safety of infliximab (IFX) in children with ulcerative colitis (UC) have not been well-evaluated. Here, we reviewed the long-term durability and safety of IFX in our single center pediatric cohort with UC. Methods: This retrospective study included 20 children with UC who were administered IFX. Results: For induction, 5 mg/kg IFX was administered at weeks 0, 2, and 6, followed by every 8 weeks for maintenance. The dose and interval of IFX were adjusted depending on clinical decisions. Corticosteroid (CS)-free remission without dose escalation (DE) occurred in 30% and 25% of patients at weeks 30 and 54, respectively. Patients who achieved CS-free remission without DE at week 30 sustained long-term IFX treatment without colectomy. However, one-third of the patients discontinued IFX treatment because of a primary nonresponse, and one-third experienced secondary loss of response (sLOR). IFX durability was higher in patients administered IFX plus azathioprine for >6 months. Four of five patients with very early onset UC had a primary nonresponse. Infusion reactions (IRs) occurred in 10 patients, resulting in discontinuation of IFX in four of these patients. No severe opportunistic infections occurred, except in one patient who developed acute focal bacterial nephritis. Three patients developed psoriasis-like lesions. Conclusion: IFX is relatively safe and effective for children with UC. Clinical remission at week 30 was associated with long-term durability of colectomy-free IFX treatment. However, approximately two-thirds of the patients were unable to continue IFX therapy because of primary nonresponse, sLOR, IRs, and other side effects.
Abstract
Purpose: The long-term efficacy and safety of infliximab (IFX) in children with ulcerative colitis (UC) have not been well-evaluated. Here, we reviewed the long-term durability and safety of IFX in our single center pediatric cohort with UC. Methods: This retrospective study included 20 children with UC who were administered IFX. Results: For induction, 5 mg/kg IFX was administered at weeks 0, 2, and 6, followed by every 8 weeks for maintenance. The dose and interval of IFX were adjusted depending on clinical decisions. Corticosteroid (CS)-free remission without dose escalation (DE) occurred in 30% and 25% of patients at weeks 30 and 54, respectively. Patients who achieved CS-free remission without DE at week 30 sustained long-term IFX treatment without colectomy. However, one-third of the patients discontinued IFX treatment because of a primary nonresponse, and one-third experienced secondary loss of response (sLOR). IFX durability was higher in patients administered IFX plus azathioprine for >6 months. Four of five patients with very early onset UC had a primary nonresponse. Infusion reactions (IRs) occurred in 10 patients, resulting in discontinuation of IFX in four of these patients. No severe opportunistic infections occurred, except in one patient who developed acute focal bacterial nephritis. Three patients developed psoriasis-like lesions. Conclusion: IFX is relatively safe and effective for children with UC. Clinical remission at week 30 was associated with long-term durability of colectomy-free IFX treatment. However, approximately two-thirds of the patients were unable to continue IFX therapy because of primary nonresponse, sLOR, IRs, and other side effects.
참고문헌 (19)
- Benchimol EI, "Epidemiology of pediatric inflammatory bowel disease : a systematic review of international trends", Inflamm Bowel Dis, 17, pp.423~439 (2011)
- Van Limbergen J, "Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease", Gastroenterology, 135, pp.1114~1122 (2008)
- Hyams JS, "Outcome following infliximab therapy in children with ulcerative colitis", Am J Gastroenterol, 105, pp.1430~1436 (2010)
- Hyams J, "Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children", Gastroenterology, 132, pp.863~873 (2007)
- Naviglio S, "Causes of treatment failure in children with inflammatory bowel disease treated with infliximab : a pharmacokinetic study", J Pediatr Gastroenterol Nutr, 68, pp.37~44 (2019)
- Birimberg-Schwartz L, "Development and validation of diagnostic criteria for IBD subtypes including IBD-unclassified in children : a multicentre study from the pediatric IBD Porto group of ESPGHAN", J Crohn's Colitis, 11, pp.1078~1084 (2017)
- Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease : the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
- Turner D, "Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study", Gastroenterology, 133, pp.423~432 (2007)
- Hyams J, "Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis", Clin Gastroenterol Hepatol, 10, pp.391~399 (2012)
- Takeuchi I, "Infliximab for very early-onset inflammatory bowel disease : a tertiary center experience in Japan", J Gastroenterol Hepatol, 35, pp.593~600 (2020)
- Turner D, "Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition", J Pediatr Gastroenterol Nutr, 67, pp.292~310 (2018)
- Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn's disease", N Engl J Med, 362, pp.1383~1395 (2010)
- Lichtenstein GR, "Clinical trial : benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials", Aliment Pharmacol Ther, 30, pp.210~226 (2009)
- Cheng J, "Concomitant therapy with immunomodulator enhances infliximab durability in pediatric inflammatory bowel disease", Inflamm Bowel Dis, 23, pp.1762~1773 (2017)
- Kotlyar DS, "Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine : a meta-analysis", Clin Gastroenterol Hepatol, 13, pp.847~858 (2015)[DOI]
- Sandborn WJ, "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis", Gastroenterology, 146, pp.85~95 (2014)
- Hyams JS, "Subcutaneous golimumab in pediatric ulcerative colitis : pharmacokinetics and clinical benefit", Inflamm Bowel Dis, 23, pp.2227~2237 (2017)
- Hiremath G, "Infliximab-induced psoriasis in children with inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 52, pp.230~232 (2011)
- Courbette O, "Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 69, pp.189~193 (2019)